Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis ... s pipeline includes VX-522, a CFTR mRNA ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that ... One is from ...

VX-522: The multiple ascending dose (MAD ... Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 ...

VX-522: The multiple ascending dose (MAD ... Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare ... One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat ...

APOL1-Mediated Kidney Disease (AMKD) – Inaxaplin (VX-147) Vertex continues to enroll and dose patients ... life-shortening genetic diseases — cystic fibrosis, sickle cell disease and ...

We now have five approved medicines in cystic fibrosis ... data releases that we expect to share this year. The first is VX-522, our mRNA program in partnership with Moderna for the last 10% ...

About Vertex Pharmaceuticals Incorporated and Biogen Inc. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis ...